Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Immunocore Holdings plc

Immunocore to present at upcoming investor conferences
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore reports second quarter financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore to report second quarter 2025 financial results and host call on August 7, 2025
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore to present at the 2025 Jefferies Global Healthcare Conference
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore reports first quarter financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore to present at upcoming investor conferences
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore to present at upcoming investor conferences
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore reports fourth quarter and full year 2024 financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore to present at upcoming investor conferences
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore reports third quarter financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore to present at the 2024 Cantor Global Healthcare Conference
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore announces transition of Chief Financial Officer
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore reports second quarter financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore to report second quarter 2024 financial results and host call on August 8, 2024
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore to present at the Jefferies Global Healthcare Conference
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore reports first quarter financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.